Camlin Fine Sciences Limited

BSE:532834 Stock Report

Market Cap: ₹25.5b

Camlin Fine Sciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Ashish Dandekar

Chief executive officer

₹28.2m

Total compensation

CEO salary percentage54.61%
CEO tenure19.5yrs
CEO ownership10.3%
Management average tenure4.9yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

Narrative Update • Jun 23

532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift

Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.
Narrative Update • Jun 06

532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring

Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.
Narrative Update • May 22

532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions

Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).
Narrative Update • Apr 26

532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions

Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).
Narrative Update • Apr 11

532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions

Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).
Narrative Update • Mar 25

532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential

Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Mar 10

532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential

Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Feb 24

532834: Upcoming Results Review Will Support Long Term Upside Potential

Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Feb 09

532834: Upcoming Board And Director Decisions Will Support Long Term Upside

Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative Update • Jan 25

532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside

Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).
Narrative Update • Jan 11

532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside

Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.
Narrative Update • Dec 24

532834: Share Swap And Governance Stability Will Drive Long Term Returns

Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.
Narrative Update • Dec 10

532834: Share Swap Acquisition Will Drive Long Term Returns

Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).
Narrative Update • Nov 26

532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns

Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.
Narrative Update • Nov 11

532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure

Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.
New Narrative • Sep 04

Tariff Benefits And Safety Trends Will Boost US And Europe

Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.

CEO Compensation Analysis

How has Ashish Dandekar's remuneration changed compared to Camlin Fine Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-₹274m

Dec 31 2025n/an/a

-₹141m

Sep 30 2025n/an/a

₹187m

Jun 30 2025n/an/a

₹825m

Mar 31 2025₹28m₹15m

₹685m

Dec 31 2024n/an/a

-₹2b

Sep 30 2024n/an/a

-₹2b

Jun 30 2024n/an/a

-₹1b

Mar 31 2024₹29m₹15m

₹651m

Dec 31 2023n/an/a

-₹8m

Sep 30 2023n/an/a

₹350m

Jun 30 2023n/an/a

₹674m

Mar 31 2023₹26m₹14m

₹577m

Dec 31 2022n/an/a

₹581m

Sep 30 2022n/an/a

₹628m

Jun 30 2022n/an/a

₹442m

Mar 31 2022₹20m₹12m

₹650m

Dec 31 2021n/an/a

₹598m

Sep 30 2021n/an/a

₹465m

Jun 30 2021n/an/a

₹579m

Mar 31 2021₹18m₹11m

₹510m

Dec 31 2020n/an/a

₹394m

Sep 30 2020n/an/a

₹291m

Jun 30 2020n/an/a

₹302m

Mar 31 2020₹18m₹11m

₹303m

Compensation vs Market: Ashish's total compensation ($USD295.87K) is above average for companies of similar size in the Indian market ($USD167.95K).

Compensation vs Earnings: Ashish's compensation has been consistent with company performance over the past year.

CEO

Ashish Dandekar (62 yo)

19.5yrs
Tenure
₹28,216,000
Compensation

Mr. Ashish Subhash Dandekar serves as the Chairman of Board at Camlin Fine Sciences Limited since June 17, 2021. He has been the Managing Director of Camlin Fine Sciences Limited (formerly known as Camlin...

Leadership Team

NamePositionTenureCompensationOwnership
Ashish Dandekar
Chairman & MDno data₹28.22m10.34%
₹ 2.6b
Nirmal Momaya
MD & Director5.1yrs₹24.56m1.88%
₹ 478.7m
Arjun Dukane
Executive Director of Technical & Executive Directorno data₹11.98m0.10%
₹ 25.9m
Santosh Parab
Chief Financial Officer9.4yrsno datano data
Nilesh Jadhav
Chief Operating Officer2.6yrsno datano data
Rahul Sawale
Company Secretary4.7yrs₹1.39mno data
Raghunath Bal
Global Head of ITno datano datano data
Rajani Dandekar
Management Consultantno datano datano data
4.9yrs
Average Tenure
59.5yo
Average Age

Experienced Management: 532834's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ashish Dandekar
Chairman & MD19.5yrs₹28.22m10.34%
₹ 2.6b
Nirmal Momaya
MD & Director11.9yrs₹24.56m1.88%
₹ 478.7m
Arjun Dukane
Executive Director of Technical & Executive Director8.1yrs₹11.98m0.10%
₹ 25.9m
Abeezar Faizullabhoy
Independent Director1.4yrs₹600.00k0.068%
₹ 17.4m
Harsha Raghavan
Non-Executive Non-Independent Director5.9yrsno datano data
Pradip Kanakia
Non-Executive Independent Director4.8yrs₹2.45mno data
Anagha Dandekar
Non-Executive Non-Independent Director8.8yrs₹700.00k1.57%
₹ 400.6m
Joseph Conrad D'Souza
Independent Director5.8yrs₹2.46mno data
Mahabaleshwar Palekar
Independent Non-Executive Director5.6yrs₹2.64m0.0031%
₹ 795.3k
Amol Shah
Independent Director6.9yrs₹2.18mno data
Radhika Dudhat
Independent Director1.3yrs₹125.00kno data
Jens Nieuwenborgh
Non-Executive Non-Independent Director1.3yrsno datano data
5.9yrs
Average Tenure
60.5yo
Average Age

Experienced Board: 532834's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 20:28
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camlin Fine Sciences Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ankur PeriwalAxis Capital Limited
Abhishek NavalgundCentrum Broking Limited
Satish KumarCGS International